# Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

> **NCT04640233** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Dr. Reddy's Laboratories Limited** · enrollment: 1600 (actual)

## Conditions studied

- COVID-19 Prevention

## Interventions

- **BIOLOGICAL:** Gam-COVID-Vac
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04640233
- **Lead sponsor:** Dr. Reddy's Laboratories Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-30
- **Primary completion:** 2021-08
- **Final completion:** 2021-09
- **Target enrollment:** 1600 (ACTUAL)
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640233, "Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04640233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*